Loading...
•
Sep 30, 2020
Sangamo Q3 2020 Earnings Report
Reported business highlights and third quarter 2020 financial results.
Key Takeaways
Sangamo Therapeutics reported a decrease in net loss attributable to Sangamo for the third quarter ended September 30, 2020, with revenues increasing compared to the same period in 2019. The company also highlighted clinical execution momentum across its portfolio and the completion of research activities in its ALS program partnered with Pfizer.
Earned a $30 million milestone from Pfizer for the dosing of the first patient in the registrational Phase 3 AFFINE study of investigational hemophilia A gene therapy giroctocogene fitelparvovec (SB-525).
Pfizer provided updated data from the Phase 1/2 Alta study of giroctocogene fitelparvovec demonstrating tolerability, clinically meaningful factor levels with no bleeds and no prophylactic factor use through up to 85 weeks in the longest patient treated in the highest dose cohort.
Completed dosing of the first two patients in the Phase 1/2 STAAR study evaluating our investigational ST-920 gene therapy in Fabry disease.
Completed research activities in our collaboration with Pfizer to develop gene regulation therapies using zinc finger protein transcription factors for the treatment of C9ORF72-related Amyotrophic Lateral Sclerosis (ALS).
Forward Guidance
Revised full year operating expense guidance was initially provided on February 28, 2020 and revised on August 5, 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...